KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Working Capital Changes (2018 - 2026)

Moderna (MRNA) has disclosed Other Working Capital Changes for 9 consecutive years, with -$54.0 million as the latest value for Q1 2026.

  • For Q1 2026, Other Working Capital Changes fell 17.39% year-over-year to -$54.0 million; the TTM value through Mar 2026 reached -$161.0 million, up 12.97%, while the annual FY2025 figure was -$153.0 million, 5.52% down from the prior year.
  • Other Working Capital Changes hit -$54.0 million in Q1 2026 for Moderna, up from -$237.0 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $212.0 million in Q1 2023 and bottomed at -$1.6 billion in Q2 2022.
  • Average Other Working Capital Changes over 5 years is -$324.5 million, with a median of -$70.0 million recorded in 2023.
  • Year-over-year, Other Working Capital Changes surged 317.14% in 2024 and then tumbled 6700.0% in 2025.
  • Moderna's Other Working Capital Changes stood at -$1.5 billion in 2022, then surged by 39.5% to -$887.0 million in 2023, then soared by 67.08% to -$292.0 million in 2024, then grew by 18.84% to -$237.0 million in 2025, then surged by 77.22% to -$54.0 million in 2026.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$54.0 million, -$237.0 million, and -$66.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.